A range of insulin analogues have been commercially developed by varying the amino acid sequences of natural insulin, hence altering its ADME (adsorption, distribution, metabolism and excretion) characteristics in glycaemic control. Insulin analogues are generally either faster-acting (i.e. offering a better post-prandial profile) or longer-acting (i.e. to supply the basal level during the day or providing overnight control) than natural insulin, offering advantages for diabetes mellitus management.
Insulin analogues are recombinant proteins, often produced in microbial expression systems and are commonly purified using a combination of downstream process steps such as reverse-phase HPLC, ion exchange or size exclusion chromatography. Due to the growing demand to reduce the number of process steps and overall cost of purifying insulin analogues, Prometic Bioseparations Ltd (PBL) has developed a high performance synthetic ligand affinity chromatography adsorbent which is compatible with large-scale process applications.
Insulin Adsorbent shares the same chemistry as PBL’s proven Mimetic Ligand™ adsorbents and provides high yields and purities for naturally occurring forms of insulin and insulin analogues from a variety of sources and is alkali resistant, robust, non-toxic and is designed for use in cGMP manufacturing of biological molecules.
• Uniform particle size PuraBead® 6HF easy to pack
• Excellent flow properties
• Selective for most forms of insulin including single chain & two chain insulin
• High purities & yields
• Cost effective & reliable
• Easy to clean robust, long life adsorbent